PTCT PTC Therapeutics, Inc. Quick Ratio

The PTC Therapeutics, Inc. (PTCT) ecosystem focuses on combating rare genetic pathologies, creating a vital support environment. The final quick ratio demonstrates the company's solvency, with the current level sitting around 3.23. This financial stability is bolstered by seamless global drug delivery channels and the commercial success of Translarna and Upstaza, alongside a substantial cash reserve.

High barriers to entry in the orphan drug segment provide PTC Therapeutics, Inc. (PTCT) with stable margins and financial autonomy. Analyzing the historical snapshot of current liquidity on GURU.Markets, an investor can see the company's ability to cover short-term liabilities solely through cash and accounts receivable, excluding inventory. This conservative approach confirms high solvency and the business's resilience to sudden market shocks.